ArticleScientific reports2022
Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Formulation of Benzoyl Peroxide Microsponge-based Transdermal Gel for Acne Infection and Its Evaluation.Pharmaceutical nanotechnology · 2026Article
- Microsponge Drug Delivery Systems: Advancing the Therapeutic Efficacy of Anti-Inflammatory Medications.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026Review
- Formulation and Evaluation of Microsponges-loaded Transdermal Gel for the Management of Osteoarthritis.Recent advances in inflammation & allergy drug discovery · 2025Article
- Acne Vulgaris-Novel Treatment Options and Factors Affecting Therapy Adherence: A Narrative Review.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to deliver Tazarotene (TZR) in a controlled manner to reduce adverse effects in the form of a microsponge-based gel. It adopts the methodology of a similar study by the undersigned authors with respect to the drug Clindamycin. Under both studies, the methodology used is emulsion solvent diffusion. Accordingly, we altered the concentrations of polymer and emulsifier to generate four formulations of TZR microsponges. Additionally, we used two types of emulsifiers and two types of solvents to develop two further microsponge formulations. We then studied the physical properties of each formulation, as well as drug-polymer interactions. Echoing findings from our prior study of Clindamycin, we found that microsponge formulations coded by T1 and T3 had superior production yield and entrapment efficiency, and their particle size was suitable for dermal application. As in the prior Clindamycin study, each of the T1 and T3 microsponge formulations were incorporated into a Carbopol gel and evaluated in vitro. The optimal formulation was found to be the microsponge formulation gel T8, which released 87.63% of TZR over 12 h. No significant interactions between the drug and excipients were found through Fourier transform infrared spectroscopy and differential scanning calorimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.